JBIO
Jade Biosciences, Inc.- Healthcare
- Biotechnology
- $928M market cap
Forecast run · Oct 29, 2026Upside rank 911 of 3,186
Model Signal
ForecastQ Daily Probabilities
36.4%
46.2%
26.7%
Analyst Consensus
Recommendation2.00/5 Buy
Last price$14.59
Price target$48.40
Implied move+231.7%
Analysts4
ForecastQ Portfolios
JBIO is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.